The FDA has approved Yeztugo (lenacapavir), a groundbreaking HIV-prevention injection by Gilead Sciences, which shows near-elimination of HIV transmission with biannual doses, significantly outperforming existing oral medications. Advocates express hope that this advancement could drastically reduce HIV infections in the U.S., though concerns about access and insurance coverage remain due to its high cost and potential political barriers.
